Christopher Raymond

Chris Raymond is a co-founder and the Chief Scientific Officer of Salish Bioscience. In 2018, he recognized an acute need to better serve the needs of cancer patients by improving the performance of NGS-based assays used to characterize circulating, cell-free DNA fragments, and so embarked on a multi-year, self-funded exploration of alternative technologies. The resulting inventions from that effort form the basis of the Salish diagnostic platform. Chris is also the co-founder of Ripple Biosolutions, a company that is leveraging his cfDNA purification methods to provide bulk quantities of highly-purified control cfDNA to research laboratories across the globe. Chris cofounded Resolution Bioscience in 2012, a liquid biopsy company that is now a wholly-owned subsidiary of Agilent Technologies.

Chris’s interest in genomics began in 1999 when he served as a Scientist in the University of Washington Genome Center under Dr. Maynard Olson. With the completion of the first draft of the Human Genome, Chris moved to Rosetta Inpharmatics (Merck & Co.) where he invented technologies for the characterization of alternatively spliced RNA transcripts and for genome-wide profiling of microRNA expression patterns. He is one of the earliest adopters of next-generation DNA sequencing technologies, and he has been continuously active in creating and applying NGS methods ever since. Chris received his BS in Chemistry from the University of California, Santa Cruz in 1982 and his Ph.D. in Chemistry from the University of Oregon in 1990.